The Claim

Once-weekly subcutaneous semaglutide at a dose of 2.4 mg causes a mean reduction in body weight of 10.5% from baseline in patients with MASH and fibrosis stage 2 or 3, compared to a 2.0% reduction with placebo (estimated difference, -8.5 percentage points; 95% CI, -9.6 to -7.4; P<0.001) at 72 weeks, a magnitude of weight loss that is clinically meaningful and likely contributes to the histological improvements.

Source: Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
88score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect
1 study reviewed
In plain English

Semaglutide reduces body weight by 10.5% in people with MASH and liver fibrosis stage 2 or 3, compared to a 2.0% reduction with placebo, at 72 weeks. This weight loss is large enough to improve liver health.

See the scientific wording

Once-weekly subcutaneous semaglutide at a dose of 2.4 mg causes a mean reduction in body weight of 10.5% from baseline in patients with MASH and fibrosis stage 2 or 3, compared to a 2.0% reduction with placebo (estimated difference, -8.5 percentage points; 95% CI, -9.6 to -7.4; P<0.001) at 72 weeks, a magnitude of weight loss that is clinically meaningful and likely contributes to the histological improvements.

Why this might work

Semaglutide makes the brain feel full, so people eat less and lose weight. Losing weight reduces the amount of fat and toxic substances in the liver. This stops the liver from making harmful fats called ceramides and a waste product called oxalate, which damage the liver. It also repairs the liver's blood vessels, reducing swelling and scarring. All of this helps the liver get healthier.

Supported mechanismbased on 1 study

What the research says

1 study
  1. Study: Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.

    The study found that people with fatty liver disease who take semaglutide lose about 10.5% of their body weight, just like the claim says, and they also had less liver inflammation and scarring, so the claim is correct.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.